Jack Phillips Sells 26,545 Shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Stock

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Jack Phillips sold 26,545 shares of Accelerate Diagnostics stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $0.86, for a total value of $22,828.70. Following the completion of the sale, the chief executive officer now directly owns 129,726 shares in the company, valued at approximately $111,564.36. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Jack Phillips also recently made the following trade(s):

• On Wednesday, April 17th, Jack Phillips sold 26,735 shares of Accelerate Diagnostics stock. The shares were sold at an average price of $0.78, for a total value of $20,853.30.
• On Thursday, April 4th, Jack Phillips sold 15,887 shares of Accelerate Diagnostics stock. The shares were sold at an average price of $0.88, for a total value of $13,980.56.
• On Thursday, February 1st, Jack Phillips sold 494 shares of Accelerate Diagnostics stock. The shares were sold at an average price of $1.30, for a total value of $642.20.

Accelerate Diagnostics Price Performance

Shares of NASDAQ:AXDX opened at $0.77 on Friday. The business’s 50 day simple moving average is $1.00 and its 200-day simple moving average is $3.20. The firm has a market capitalization of $16.68 million, a price-to-earnings ratio of -0.16 and a beta of 0.52. Accelerate Diagnostics, Inc. has a 12 month low of $0.73 and a 12 month high of $11.90.

Institutional Investors Weigh In On Accelerate Diagnostics

Institutional investors have recently modified their holdings of the company. Tejara Capital Ltd acquired a new position in shares of Accelerate Diagnostics during the 3rd quarter worth approximately $78,000. Griffin Asset Management Inc. raised its position in shares of Accelerate Diagnostics by 3.0% during the 4th quarter. Griffin Asset Management Inc. now owns 1,219,724 shares of the medical research company’s stock worth $4,781,000 after purchasing an additional 35,146 shares during the last quarter. TCI Wealth Advisors Inc. acquired a new position in shares of Accelerate Diagnostics during the 3rd quarter worth approximately $337,000. Sonora Investment Management Group LLC acquired a new position in shares of Accelerate Diagnostics during the 3rd quarter worth approximately $63,000. Finally, Two Sigma Investments LP acquired a new position in shares of Accelerate Diagnostics during the 3rd quarter worth approximately $329,000. Hedge funds and other institutional investors own 17.14% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on AXDX. Craig Hallum lowered their price objective on Accelerate Diagnostics from $2.00 to $1.00 and set a “hold” rating on the stock in a report on Monday, April 1st. William Blair reissued an “outperform” rating on shares of Accelerate Diagnostics in a research note on Tuesday, April 2nd. Finally, StockNews.com began coverage on Accelerate Diagnostics in a research note on Friday, April 12th. They set a “hold” rating on the stock.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.